Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the latest data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company’s Phase 2 CALLIPER trial in progressive multiple sclerosis (MS).

The discussion centered on two posters shared at the conference: one focusing on MRI outcomes and the other exploring EBV (Epstein-Barr Virus) reactivation. Muehler explained that vidofludimus calcium demonstrated reductions in gadolinium-enhancing and T2 lesions as well as slowly expanding lesions (SELs) - indicators of acute and chronic inflammation in MS, respectively.

He outlined how MRI scans detected fewer SELs in treated patients, providing early clinical signs that vidofludimus calcium could address both peripheral and central nervous system inflammation in progressive MS.

“These data from the CALLIPER trial really show for the first time that there's also clinical evidence that vidofludimus calcium is causing a statistically significant reduction in EBV reactivation with treatment over time as compared to placebo,” said Muehler.

The EBV-related findings were particularly important, as mounting evidence suggests the virus is a necessary condition for MS. The company measured T-cell receptor repertoires and found a clear drop in EBV antigens among patients treated with vidofludimus calcium, suggesting reduced reactivation activity.

Looking ahead, Muehler pointed to 2026 as a potential pivotal year, with the company expecting readouts from its two phase 3 trials in relapsing MS involving over 2,000 patients. These results are expected to inform regulatory submissions and could bring Immunic’s treatment closer to market.

Visit Proactive's YouTube channel for more interviews, and don't forget to give this video a like, subscribe to our channel, and enable notifications so you never miss an update.

#ImmunicInc #MSResearch #ProgressiveMS #VidofludimusCalcium #EBV #MultipleSclerosis #BiotechNews #ClinicalTrials #MSAwareness #MRIResearch #Neuroscience #PharmaInnovation #SELlesions #Phase2Trial #MSInflammation